Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival-Reference-Cited by-同舟云学术

Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival

Published:2019-12-10 Issue:1 Volume:146 Page:163-170
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Schaff Lauren R.^ORCID,Yan Dongyao,Thyparambil Sheeno,Tian Yuan,Cecchi Fabiola,Rosenblum Marc^ORCID,Reiner Anne S.^ORCID,Panageas Katherine S.,Hembrough Todd,Lin Andrew L.^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-019-03358-x.pdf

Reference32 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) European Organisation for Research and Treatment of Cancer Brain Tumor. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

2. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718

3. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi:https://doi.org/10.1056/NEJM200011093431901

4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331

5. Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G (2019) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 21:167–178. https://doi.org/10.1093/neuonc/noy132

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A proteome-level view of brain tumors for a better understanding of novel diagnosis, prognosis, and therapy;Expert Review of Proteomics;2023-11-28

2. Dissecting the Methylomes of EGFR-Amplified Glioblastoma Reveals Altered DNA Replication and Packaging, and Chromatin and Gene Silencing Pathways;Cancers;2023-07-07

3. Gene Targets of CAR-T Cell Therapy for Glioblastoma;Cancers;2023-04-18

4. Temozolomide: a cytostatic drug that is still important today;Acta Poloniae Pharmaceutica - Drug Research;2023-03-03

5. The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma;Frontiers in Neuroscience;2023-01-11